Laboratory Corporation of America Holdings (NYSE:LH) had its price objective boosted by Barclays PLC from $182.00 to $183.00 in a research note released on Thursday. Barclays PLC currently has an overweight rating on the medical research company’s stock.

Other equities research analysts also recently issued reports about the company. Craig Hallum restated a buy rating and set a $179.00 price objective (up from $157.00) on shares of Laboratory Corporation of America Holdings in a research report on Thursday. Credit Suisse Group downgraded Laboratory Corporation of America Holdings to a hold rating and set a $146.00 price objective on the stock. in a research report on Thursday, July 13th. They noted that the move was a valuation call. Zacks Investment Research upgraded Laboratory Corporation of America Holdings from a sell rating to a hold rating in a research report on Thursday. BidaskClub upgraded Laboratory Corporation of America Holdings from a buy rating to a strong-buy rating in a research report on Wednesday, June 28th. Finally, Jefferies Group LLC decreased their price objective on Laboratory Corporation of America Holdings from $159.00 to $157.00 and set a hold rating on the stock in a research report on Friday, April 28th. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of Buy and a consensus price target of $158.42.

Laboratory Corporation of America Holdings (LH) traded down 0.52% during trading on Thursday, reaching $159.23. The company had a trading volume of 362,025 shares. The company has a market capitalization of $16.31 billion, a PE ratio of 22.30 and a beta of 0.93. The firm’s 50 day moving average is $150.88 and its 200 day moving average is $142.56. Laboratory Corporation of America Holdings has a one year low of $119.51 and a one year high of $164.22.

Laboratory Corporation of America Holdings (NYSE:LH) last issued its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.40 by $0.07. Laboratory Corporation of America Holdings had a return on equity of 16.85% and a net margin of 7.57%. The business had revenue of $2.50 billion for the quarter, compared to the consensus estimate of $2.47 billion. During the same period in the prior year, the business posted $2.36 earnings per share. The company’s quarterly revenue was up 4.9% compared to the same quarter last year. On average, equities research analysts predict that Laboratory Corporation of America Holdings will post $9.47 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Laboratory Corporation of America Holdings (NYSE:LH) Price Target Raised to $183.00 at Barclays PLC” was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/laboratory-corporation-of-america-holdings-nyselh-price-target-raised-to-183-00-at-barclays-plc/1464288.html.

In related news, SVP Lance Berberian sold 3,613 shares of the stock in a transaction that occurred on Monday, May 22nd. The stock was sold at an average price of $139.84, for a total value of $505,241.92. Following the transaction, the senior vice president now owns 5,789 shares of the company’s stock, valued at $809,533.76. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Jean-Luc Belingard sold 992 shares of the stock in a transaction that occurred on Tuesday, May 9th. The stock was sold at an average price of $142.19, for a total value of $141,052.48. Following the completion of the transaction, the director now directly owns 32,935 shares in the company, valued at approximately $4,683,027.65. The disclosure for this sale can be found here. Corporate insiders own 0.90% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in LH. National Pension Service boosted its position in shares of Laboratory Corporation of America Holdings by 0.8% in the first quarter. National Pension Service now owns 89,705 shares of the medical research company’s stock valued at $12,916,000 after buying an additional 751 shares during the period. Gulf International Bank UK Ltd boosted its position in shares of Laboratory Corporation of America Holdings by 9.4% in the first quarter. Gulf International Bank UK Ltd now owns 32,581 shares of the medical research company’s stock valued at $4,674,000 after buying an additional 2,800 shares during the period. Sheets Smith Wealth Management purchased a new position in shares of Laboratory Corporation of America Holdings during the first quarter valued at about $215,000. Forte Capital LLC ADV boosted its position in shares of Laboratory Corporation of America Holdings by 4.7% in the first quarter. Forte Capital LLC ADV now owns 30,156 shares of the medical research company’s stock valued at $4,326,000 after buying an additional 1,340 shares during the period. Finally, Raymond James Trust N.A. boosted its position in shares of Laboratory Corporation of America Holdings by 29.0% in the first quarter. Raymond James Trust N.A. now owns 3,115 shares of the medical research company’s stock valued at $447,000 after buying an additional 701 shares during the period. 91.58% of the stock is currently owned by institutional investors.

Laboratory Corporation of America Holdings Company Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Analyst Recommendations for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with Analyst Ratings Network's FREE daily email newsletter.